Sorrel Wolowacz | Head European Health Economics
R.T.I. Health Solutions
Sorrel Wolowacz is a seasoned professional in the field of health economics, currently serving as the Head of European Health Economics at R.T.I. Health Solutions. With a strong background in health economics and a passion for improving access to healthcare for rare disease patients, Sorrel brings a wealth of knowledge and experience to her role.
With a track record of success in developing and implementing health economic strategies, Sorrel is dedicated to finding innovative solutions to the challenges faced by orphan drug and rare disease communities. Her expertise lies in conducting cost-effectiveness analyses, health technology assessments, and real-world evidence studies to demonstrate the value of treatments for rare diseases.
Sorrel is a thought leader in the field of health economics, regularly contributing her insights and expertise to industry conferences and events. Her commitment to advancing the field of orphan drugs and rare diseases makes her a valuable asset to any organization looking to make a positive impact on patient outcomes.
At the World Orphan Drug Congress USA 2025, Sorrel Wolowacz will share her expertise and insights on the latest trends and developments in health technoligy assessment, including the new HTA Regulation in Europe (Joint Clinical Assessment) and implications for orphan drugs and rare diseases. Attendees can expect to gain valuable knowledge and practical strategies for navigating the complex landscape of rare disease healthcare economics from one of the industry's leading experts.
Appearances:
Day 2 - World Orphan Drug Congress USA 2025 @ 14:20
Panel: Giving voice to rare diseases during joint clinical assessment
Starting January 13, 2028, orphan medicines will be required to undergo Joint Clinical Assessments (JCAs) as part of the EU Health Technology Assessment Regulation (HTAR). Manufacturers must prepare and submit JCA dossiers documenting the comparative efficacy and safety of their products against relevant comparators across EU member states. However, applying the same rigorous standards to orphan medicines as to other drugs presents unique challenges, including small patient populations, limited evidence, treatment variability, and high levels of uncertainty.
This panel will feature Victor Maertens, Government Affairs Director at EUCOPE and a leading expert in European policy and government affairs, Patrick Hopkinson an experienced representative from the pharmaceutical industry, and Sorrel Wolowacz, Vice President at RTI Health Solutions, who is an expert in innovative methods for demonstrating value in orphan medicines. The session will be moderated by Anne Heyes, Vice President at RTI Health Solutions.
The panelists will share insights from policy, patient advocacy, and industry perspectives on how they are preparing for these upcoming changes. They will discuss strategies for overcoming challenges associated with JCAs and highlight key advocacy efforts aimed at ensuring that the unique needs of orphan medicines are addressed under the new framework.
This session is essential for stakeholders seeking to navigate the evolving regulatory landscape while maintaining access to life-saving therapies for rare disease patients.
Sponsored by RTI Health Solutions.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events